Shares of Intellia Therapeutics Inc. NTLA rallied about 10% in premarket trading on Thursday after the company said the Food and Drug Administration will allow its experimental CRISPR therapy to move into the Phase 2 part of the Phase 1/2 clinical trial. The single-dose therapy is being assessed as a treatment for hereditary angioedema, a rare disorder that causes severe swelling. Intellia plans to share data from the Phase 1 part of the study later this year. The company’s stock is up 16.8% so far this year, while the broader S&P 500 SPX has gained 3.2%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
>>> Read the full story at MarketWatch.com - MarketPulse